Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials

Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials

•IL-6 inhibitors reduce the risk of death in COVID-19 hospitalized patients.•IL-6 inhibitors decrease the odds for intubation in COVID-19 hospitalized patients.•IL-6 inhibitors increase the odds for discharge in COVID-19 hospitalized patients.•This is the first meta-analysis of individualized patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of internal medicine 2022-07, Vol.101, p.41-48
Hauptverfasser: Tasoudis, Panagiotis T., Arvaniti, Christina K., Adamou, Anastasia T., Belios, Ioannis, Stone, John H., Horick, Nora, Sagris, Dimitrios, Dalekos, George N., Ntaios, George
Format: Artikel
Sprache:eng
Schlagworte:
COVID-19
Inteleukin-6
Original
SOC
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 48
container_issue
container_start_page 41
container_title European journal of internal medicine
container_volume 101
creator Tasoudis, Panagiotis T.
Arvaniti, Christina K.
Adamou, Anastasia T.
Belios, Ioannis
Stone, John H.
Horick, Nora
Sagris, Dimitrios
Dalekos, George N.
Ntaios, George
description •IL-6 inhibitors reduce the risk of death in COVID-19 hospitalized patients.•IL-6 inhibitors decrease the odds for intubation in COVID-19 hospitalized patients.•IL-6 inhibitors increase the odds for discharge in COVID-19 hospitalized patients.•This is the first meta-analysis of individualized patient data regarding COVID-19. To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was performed according to the PRISMA statement. Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible. Individual patient data were extracted from the Kaplan-Meier curves or were obtained from authors of included studies. Additionally, the reviewers independently abstracted data and assessed study quality of each eligible report. Eleven studies were identified, incorporating 7467 patients (IL-6 inhibitors: 4103, SOC: 3364). IL-6 inhibitors were associated with decreased risk for death compared to SOC at the one-stage meta-analysis (Hazard Ratio [HR]: 0.75, 95% Confidence interval [CI]: 0.69–0.82, p
doi_str_mv 10.1016/j.ejim.2022.04.004
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8986475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0953620522001406</els_id><sourcerecordid>2651687957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-6beaaf0cec2b61417b0aca9fe44f43df8dd3ff9afb483f28cd4d41f18457f68b3</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhhtR3HX1D3iQHL30mKTTXyLCsvixsOBFz6E6qbg1didjkh6Y_Rf-YzPMuujFUxW8b71V1FNVLwXfCC66N9sNbmnZSC7lhqsN5-pRdS6Gfqz5IIfH1Tkf26buJG_PqmcpbTkXPefN0-qsaZWUTa_Oq1_XPmOccf1Bvu4Y-VuaKIeYWES7GmRLiBlmyoeiMRNi8LCnuCZmKSEkrCUX41t26YtuaU92hZntIBP6zCxkYAtmqMHDfEiUmIthYRG8DQvdoS2RPscwz6XNkWBOz6snrhR8cV8vqm8fP3y9-lzffPl0fXV5UxvVilx3EwI4btDIqRNK9BMHA6NDpZxqrBusbZwbwU1qaJwcjFVWCScG1fauG6bmonp_yt2t04LWlHsjzHoXaYF40AFI_6t4utXfw14P49Cpvi0Br-8DYvi5Ysp6oWRwnsFjWJOWXSu6QqPti1WerCaGlCK6hzWC6yNLvdVHlvrIUnOlC8sy9OrvAx9G_sArhncnA5Y37QmjTqa83aCliCZrG-h_-b8BVr62DQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2651687957</pqid></control><display><type>article</type><title>Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Tasoudis, Panagiotis T. ; Arvaniti, Christina K. ; Adamou, Anastasia T. ; Belios, Ioannis ; Stone, John H. ; Horick, Nora ; Sagris, Dimitrios ; Dalekos, George N. ; Ntaios, George</creator><creatorcontrib>Tasoudis, Panagiotis T. ; Arvaniti, Christina K. ; Adamou, Anastasia T. ; Belios, Ioannis ; Stone, John H. ; Horick, Nora ; Sagris, Dimitrios ; Dalekos, George N. ; Ntaios, George</creatorcontrib><description>•IL-6 inhibitors reduce the risk of death in COVID-19 hospitalized patients.•IL-6 inhibitors decrease the odds for intubation in COVID-19 hospitalized patients.•IL-6 inhibitors increase the odds for discharge in COVID-19 hospitalized patients.•This is the first meta-analysis of individualized patient data regarding COVID-19. To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was performed according to the PRISMA statement. Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible. Individual patient data were extracted from the Kaplan-Meier curves or were obtained from authors of included studies. Additionally, the reviewers independently abstracted data and assessed study quality of each eligible report. Eleven studies were identified, incorporating 7467 patients (IL-6 inhibitors: 4103, SOC: 3364). IL-6 inhibitors were associated with decreased risk for death compared to SOC at the one-stage meta-analysis (Hazard Ratio [HR]: 0.75, 95% Confidence interval [CI]: 0.69–0.82, p&lt;0.0001) and the two-stage meta-analysis (HR: 0.85, 95%CI: 0.77–0.93, p&lt;0.001, I2 = 0.0%). Meta-regression analysis revealed that the difference in OS between the two groups was not influenced by the mean age of patients. At secondary meta-analyses, IL-6 inhibitors were associated with decreased odds for intubation OR:0.74, 95%CI:0.65–0.85, p&lt;0.001, I2=0.0%). IL-6 inhibitors were associated with increased odds for discharge compared to SOC (OR:1.28, 95% CI:1.15–1.42, p&lt;0.001, I2=0.0%). This meta-analysis of individual patient data from randomized trials shows that IL-6 inhibitors significantly reduce the risk of death compared to SOC. IL-6 inhibitors are also associated with better outcomes in terms of intubation and discharge rates compared to SOC. [Display omitted]</description><identifier>ISSN: 0953-6205</identifier><identifier>EISSN: 1879-0828</identifier><identifier>DOI: 10.1016/j.ejim.2022.04.004</identifier><identifier>PMID: 35422374</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>COVID-19 ; Inteleukin-6 ; Original ; SOC</subject><ispartof>European journal of internal medicine, 2022-07, Vol.101, p.41-48</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier B.V.</rights><rights>2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-6beaaf0cec2b61417b0aca9fe44f43df8dd3ff9afb483f28cd4d41f18457f68b3</citedby><cites>FETCH-LOGICAL-c451t-6beaaf0cec2b61417b0aca9fe44f43df8dd3ff9afb483f28cd4d41f18457f68b3</cites><orcidid>0000-0003-4701-0858 ; 0000-0002-3745-401X ; 0000-0001-7735-9474 ; 0000-0002-0629-9248</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejim.2022.04.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35422374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tasoudis, Panagiotis T.</creatorcontrib><creatorcontrib>Arvaniti, Christina K.</creatorcontrib><creatorcontrib>Adamou, Anastasia T.</creatorcontrib><creatorcontrib>Belios, Ioannis</creatorcontrib><creatorcontrib>Stone, John H.</creatorcontrib><creatorcontrib>Horick, Nora</creatorcontrib><creatorcontrib>Sagris, Dimitrios</creatorcontrib><creatorcontrib>Dalekos, George N.</creatorcontrib><creatorcontrib>Ntaios, George</creatorcontrib><title>Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials</title><title>European journal of internal medicine</title><addtitle>Eur J Intern Med</addtitle><description>•IL-6 inhibitors reduce the risk of death in COVID-19 hospitalized patients.•IL-6 inhibitors decrease the odds for intubation in COVID-19 hospitalized patients.•IL-6 inhibitors increase the odds for discharge in COVID-19 hospitalized patients.•This is the first meta-analysis of individualized patient data regarding COVID-19. To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was performed according to the PRISMA statement. Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible. Individual patient data were extracted from the Kaplan-Meier curves or were obtained from authors of included studies. Additionally, the reviewers independently abstracted data and assessed study quality of each eligible report. Eleven studies were identified, incorporating 7467 patients (IL-6 inhibitors: 4103, SOC: 3364). IL-6 inhibitors were associated with decreased risk for death compared to SOC at the one-stage meta-analysis (Hazard Ratio [HR]: 0.75, 95% Confidence interval [CI]: 0.69–0.82, p&lt;0.0001) and the two-stage meta-analysis (HR: 0.85, 95%CI: 0.77–0.93, p&lt;0.001, I2 = 0.0%). Meta-regression analysis revealed that the difference in OS between the two groups was not influenced by the mean age of patients. At secondary meta-analyses, IL-6 inhibitors were associated with decreased odds for intubation OR:0.74, 95%CI:0.65–0.85, p&lt;0.001, I2=0.0%). IL-6 inhibitors were associated with increased odds for discharge compared to SOC (OR:1.28, 95% CI:1.15–1.42, p&lt;0.001, I2=0.0%). This meta-analysis of individual patient data from randomized trials shows that IL-6 inhibitors significantly reduce the risk of death compared to SOC. IL-6 inhibitors are also associated with better outcomes in terms of intubation and discharge rates compared to SOC. [Display omitted]</description><subject>COVID-19</subject><subject>Inteleukin-6</subject><subject>Original</subject><subject>SOC</subject><issn>0953-6205</issn><issn>1879-0828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kU2LFDEQhhtR3HX1D3iQHL30mKTTXyLCsvixsOBFz6E6qbg1didjkh6Y_Rf-YzPMuujFUxW8b71V1FNVLwXfCC66N9sNbmnZSC7lhqsN5-pRdS6Gfqz5IIfH1Tkf26buJG_PqmcpbTkXPefN0-qsaZWUTa_Oq1_XPmOccf1Bvu4Y-VuaKIeYWES7GmRLiBlmyoeiMRNi8LCnuCZmKSEkrCUX41t26YtuaU92hZntIBP6zCxkYAtmqMHDfEiUmIthYRG8DQvdoS2RPscwz6XNkWBOz6snrhR8cV8vqm8fP3y9-lzffPl0fXV5UxvVilx3EwI4btDIqRNK9BMHA6NDpZxqrBusbZwbwU1qaJwcjFVWCScG1fauG6bmonp_yt2t04LWlHsjzHoXaYF40AFI_6t4utXfw14P49Cpvi0Br-8DYvi5Ysp6oWRwnsFjWJOWXSu6QqPti1WerCaGlCK6hzWC6yNLvdVHlvrIUnOlC8sy9OrvAx9G_sArhncnA5Y37QmjTqa83aCliCZrG-h_-b8BVr62DQ</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Tasoudis, Panagiotis T.</creator><creator>Arvaniti, Christina K.</creator><creator>Adamou, Anastasia T.</creator><creator>Belios, Ioannis</creator><creator>Stone, John H.</creator><creator>Horick, Nora</creator><creator>Sagris, Dimitrios</creator><creator>Dalekos, George N.</creator><creator>Ntaios, George</creator><general>Elsevier B.V</general><general>European Federation of Internal Medicine. Published by Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4701-0858</orcidid><orcidid>https://orcid.org/0000-0002-3745-401X</orcidid><orcidid>https://orcid.org/0000-0001-7735-9474</orcidid><orcidid>https://orcid.org/0000-0002-0629-9248</orcidid></search><sort><creationdate>20220701</creationdate><title>Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials</title><author>Tasoudis, Panagiotis T. ; Arvaniti, Christina K. ; Adamou, Anastasia T. ; Belios, Ioannis ; Stone, John H. ; Horick, Nora ; Sagris, Dimitrios ; Dalekos, George N. ; Ntaios, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-6beaaf0cec2b61417b0aca9fe44f43df8dd3ff9afb483f28cd4d41f18457f68b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>COVID-19</topic><topic>Inteleukin-6</topic><topic>Original</topic><topic>SOC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tasoudis, Panagiotis T.</creatorcontrib><creatorcontrib>Arvaniti, Christina K.</creatorcontrib><creatorcontrib>Adamou, Anastasia T.</creatorcontrib><creatorcontrib>Belios, Ioannis</creatorcontrib><creatorcontrib>Stone, John H.</creatorcontrib><creatorcontrib>Horick, Nora</creatorcontrib><creatorcontrib>Sagris, Dimitrios</creatorcontrib><creatorcontrib>Dalekos, George N.</creatorcontrib><creatorcontrib>Ntaios, George</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tasoudis, Panagiotis T.</au><au>Arvaniti, Christina K.</au><au>Adamou, Anastasia T.</au><au>Belios, Ioannis</au><au>Stone, John H.</au><au>Horick, Nora</au><au>Sagris, Dimitrios</au><au>Dalekos, George N.</au><au>Ntaios, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials</atitle><jtitle>European journal of internal medicine</jtitle><addtitle>Eur J Intern Med</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>101</volume><spage>41</spage><epage>48</epage><pages>41-48</pages><issn>0953-6205</issn><eissn>1879-0828</eissn><abstract>•IL-6 inhibitors reduce the risk of death in COVID-19 hospitalized patients.•IL-6 inhibitors decrease the odds for intubation in COVID-19 hospitalized patients.•IL-6 inhibitors increase the odds for discharge in COVID-19 hospitalized patients.•This is the first meta-analysis of individualized patient data regarding COVID-19. To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was performed according to the PRISMA statement. Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible. Individual patient data were extracted from the Kaplan-Meier curves or were obtained from authors of included studies. Additionally, the reviewers independently abstracted data and assessed study quality of each eligible report. Eleven studies were identified, incorporating 7467 patients (IL-6 inhibitors: 4103, SOC: 3364). IL-6 inhibitors were associated with decreased risk for death compared to SOC at the one-stage meta-analysis (Hazard Ratio [HR]: 0.75, 95% Confidence interval [CI]: 0.69–0.82, p&lt;0.0001) and the two-stage meta-analysis (HR: 0.85, 95%CI: 0.77–0.93, p&lt;0.001, I2 = 0.0%). Meta-regression analysis revealed that the difference in OS between the two groups was not influenced by the mean age of patients. At secondary meta-analyses, IL-6 inhibitors were associated with decreased odds for intubation OR:0.74, 95%CI:0.65–0.85, p&lt;0.001, I2=0.0%). IL-6 inhibitors were associated with increased odds for discharge compared to SOC (OR:1.28, 95% CI:1.15–1.42, p&lt;0.001, I2=0.0%). This meta-analysis of individual patient data from randomized trials shows that IL-6 inhibitors significantly reduce the risk of death compared to SOC. IL-6 inhibitors are also associated with better outcomes in terms of intubation and discharge rates compared to SOC. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35422374</pmid><doi>10.1016/j.ejim.2022.04.004</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4701-0858</orcidid><orcidid>https://orcid.org/0000-0002-3745-401X</orcidid><orcidid>https://orcid.org/0000-0001-7735-9474</orcidid><orcidid>https://orcid.org/0000-0002-0629-9248</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0953-6205
ispartof European journal of internal medicine, 2022-07, Vol.101, p.41-48
issn 0953-6205
1879-0828
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8986475
source ScienceDirect Journals (5 years ago - present)
subjects COVID-19
Inteleukin-6
Original
SOC
title Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T07%3A42%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-6%20inhibitors%20reduce%20mortality%20in%20coronavirus%20disease-2019:%20An%20individual%20patient%20data%20meta-analysis%20from%20randomized%20controlled%20trials&rft.jtitle=European%20journal%20of%20internal%20medicine&rft.au=Tasoudis,%20Panagiotis%20T.&rft.date=2022-07-01&rft.volume=101&rft.spage=41&rft.epage=48&rft.pages=41-48&rft.issn=0953-6205&rft.eissn=1879-0828&rft_id=info:doi/10.1016/j.ejim.2022.04.004&rft_dat=%3Cproquest_pubme%3E2651687957%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2651687957&rft_id=info:pmid/35422374&rft_els_id=S0953620522001406&rfr_iscdi=true